Why Viking Therapeutics Tumbled by More Than 10% This Week

News of a fresh licensing deal by a well-capitalized rival sent Viking Therapeutics (NASDAQ: VKTX) stock into something of a tailspin this week. According ... Read more

Bron:

Fool.com: The Motley Fool